Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The uses and misuses of orthogonality in aggregation studies
May 6, 2015
By: Inigo Rodriguez-Mendieta
SGS Life Science Services
Biophysical analysis, the use of physical techniques to investigate and characterize biological systems, has become increasingly important in the characterization of biologic drug candidates. A large number of analyses can be performed to determine 3D protein structure, including secondary, tertiary, and even quaternary structures of protein molecules such as monoclonal antibodies, to determine that the molecule is in a stable state. It is also possible to determine buffer conditions and degradation pathways, yielding valuable information on the impact of formulation on the stability of the protein molecule. The techniques applied in biophysical analysis can also provide information for comparability studies, which is especially important in the area of biosimilars. Biophysical analysis includes both traditional techniques for determination of secondary or tertiary structures and methods for studying the aggregation properties of biologics. These methods include site exclusion chromatography (SEC), which complements other techniques such as analytical ultracentrifugation (AUC), a very powerful but complex and slow technique. Using an orthogonal approach, techniques such as SEC, SEC-MALS (SEC with combined with multi-angle light scattering), sedimentation velocity AUC (SV-AUC), dynamic light scattering (DLS), sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-Page) and field flow fractionation (FFF) can be used for the determination of a wide range of colloidal features of biomolecules. These techniques generate valuable data that can assess bioavailability of biologic drugs and are becoming industry standards. CHOICE OF TECHNIQUE: EXPERIMENTAL STRATEGY In bioanalysis, the aim is to optimize experimental strategy to achieve the intended purpose of the study. However, each biophysical analysis technique has its limitations and no single technique provides all the information required. AUC provides information on quantification of aggregates in the absence of a stationary phase, but only gives average values of molecular weight. Thus, it is important to carefully plan which techniques to use to optimize the outcome of the study program. Most biophysical analysis techniques are orthogonal, providing information on the same properties of the compound, but each has its limitations, and therefore it is essential to build an analytical landscape that demonstrates the overall behaviour of the molecule. In general, it is usual to employ a single technique in the very early stages of biopharmaceutical discovery research when small amounts of material are used. As the development program progresses, it is more common to perform further tests using orthogonal methods. CHARACTERIZATION OF PROTEIN AGGREGATION The aggregation of biopharmaceuticals is a complex physical process and its analysis requires the use of a selection of suitable methods to build up a comprehensive dataset that would then support appropriate interpretation and scientifically sound conclusions. The orthogonal methods discussed (SV-AUC, SEC, SEC-MALS, DLS, SDS-Page and FFF) provide ways of characterizing soluble aggregates but have a number of limitations in their abilities to provide quantitative information. For efficient aggregation analysis, it is essential to make a careful selection of methods in order to minimize gaps in the resultant data because of the wide range of hydrodynamic sizes that an aggregate can have. Proper method selection ensures these data are both orthogonal and valuable, and that none of the data collected are redundant. The following discusses a number of biophysical methods in detail and shows how apparently conflicting data from techniques such as SV-AUC, SEC-MALS and DLS can be integrated. The experiments also show how a combination of these data, with results obtained from further orthogonal methods, can provide a comprehensive description of protein aggregation. The experiments describe the analysis of two proteins: a bovine IgG antibody in three different formulations, and a single formulation of -amylase, an enzyme that catalyses the hydrolysis of polysaccharides. MATERIALS AND METHODS Bovine IgG formulations A, B and C were analyzed using a range of biophysical methods, including SV-AUC (Beckman Coulter XL-A AUC), SEC-MALS (GE Ettan HPLC system and Wyatt Corporation detection technology) and DLS (Malvern Zetasizer Nano-S). Lyophilized bovine IgG was dissolved in the respective formulation buffers at concentrations of 1 mg/mL for the complete set of measurements. The -amylase, obtained from Bacillus subtilis, was formulated at pH 7 and tested using SV-AUC, SEC-MALS, DLS and SDS-Page. Lyophilized -amylase was dissolved in the respective formulation buffer at concentrations of 0.6 mg/mL (SV-AUC and SEC-MALS) for the complete set of measurements; 0.5 mg/ml for DLS; and a range of concentrations (0.8-2.0 mg/mL) for the SDS-Page measurements. Further SV-AUC measurements were made in -amylase in the range of concentrations 0.2 to 1.4 mg/mL in the absence and presence of NaCl in a 10:1 molar ratio of salt to protein. BOVINE IgG FORMULATION CASE STUDY Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC) Figure 1 shows the results of SV-AUC analysis of bovine IgG in formulation buffers A, B and C, from left to right, respectively, and Table 1 shows the relative abundance of monomers to dimers of bovine IgG in the three formulations as determined by calculating the integrated areas of the C(s) distributions obtained by fitting the SV-AUC data with SEDFIT software. The advantages and disadvantages of the SV-AUC method are: Advantages:
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !